These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 28763548

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group.
    JAMA; 2022 May 17; 327(19):1888-1898. PubMed ID: 35579642
    [Abstract] [Full Text] [Related]

  • 3. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
    Wong MG, Lv J, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Reich HN, Cattran D, Glassock R, Levin A, Jardine MJ, Wheeler DC, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group.
    Am J Nephrol; 2021 May 17; 52(10-11):827-836. PubMed ID: 34731857
    [Abstract] [Full Text] [Related]

  • 4. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul 17; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
    Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N, MAIN Trial Investigators.
    JAMA Netw Open; 2023 Feb 01; 6(2):e2254054. PubMed ID: 36745456
    [Abstract] [Full Text] [Related]

  • 6. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L, NEFIGAN Trial Investigators.
    Lancet; 2017 May 27; 389(10084):2117-2127. PubMed ID: 28363480
    [Abstract] [Full Text] [Related]

  • 7. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H.
    Clin J Am Soc Nephrol; 2014 Mar 27; 9(3):484-9. PubMed ID: 24408121
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
    Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd trial investigators.
    Lancet; 2023 Sep 09; 402(10405):859-870. PubMed ID: 37591292
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study.
    Liang M, Xiong L, Li A, Zhou J, Huang Y, Huang M, Zhang X, Shi H, Su N, Wei Y, Jiang Z.
    BMC Nephrol; 2022 Jan 21; 23(1):40. PubMed ID: 35062886
    [Abstract] [Full Text] [Related]

  • 11. The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy.
    Kim D, Lv J, Hladunewich M, Jha V, Hooi LS, Monaghan H, Shan S, Reich HN, Barbour S, Billot L, Zhang H, Perkovic V, Wong MG, TESTING trial steering committee.
    Kidney Int Rep; 2024 Jul 21; 9(7):2168-2179. PubMed ID: 39081761
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators.
    Lancet; 2023 Dec 02; 402(10417):2077-2090. PubMed ID: 37931634
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of steroid pulse therapy in combination with mizoribine following tonsillectomy for immunoglobulin A nephropathy in renally impaired patients.
    Kaneko T, Shimizu A, Tsuruoka S, Iino Y, Katayama Y.
    J Nippon Med Sch; 2013 Dec 02; 80(4):279-86. PubMed ID: 23995570
    [Abstract] [Full Text] [Related]

  • 15. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial.
    Liu H, Xu X, Fang Y, Ji J, Zhang X, Yuan M, Liu C, Ding X.
    Intern Med; 2014 Dec 02; 53(7):675-81. PubMed ID: 24694475
    [Abstract] [Full Text] [Related]

  • 16. Comparison of oral steroids with tonsillectomy plus steroid pulse therapy in patients with IgA nephropathy.
    Hoshino Y, Moriyama T, Uchida K, Tsuchiya K, Nitta K.
    Clin Exp Nephrol; 2017 Aug 02; 21(4):617-623. PubMed ID: 27549901
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov 02; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 18. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
    Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F.
    J Nephrol; 2013 Nov 02; 26(1):86-93. PubMed ID: 22460183
    [Abstract] [Full Text] [Related]

  • 19. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators.
    Kidney Int; 2021 Jul 02; 100(1):215-224. PubMed ID: 33878338
    [Abstract] [Full Text] [Related]

  • 20. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
    Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, STOP-IgAN Investigators.
    N Engl J Med; 2015 Dec 03; 373(23):2225-36. PubMed ID: 26630142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.